Vensun Pharmaceuticals Announces Launch Of Carisoprodol Tablets, USP, 250 Mg

YARDLEY, Pa.--(BUSINESS WIRE)--Vensun Pharmaceuticals, Inc. (“Vensun” or “the Company”), a privately held generic pharmaceutical company, today announced the launch of Carisoprodol Tablets USP, 250 mg, the first generic equivalent to Meda’s Soma^® 250 mg Tablets. According to IMS Health, the product had U.S. sales of approximately $16 million for the 12 months ending November 30, 2015.

“This is a critical milestone for the company. Carisoprodol is the first product approval from our development portfolio. This marks the first step towards realizing our vision of building an organization that provides affordable and high quality generics while creating value for our customers, partners and stakeholders.”

Hem Pandya, President and CEO said, “This is a critical milestone for the company. Carisoprodol is the first product approval from our development portfolio. This marks the first step towards realizing our vision of building an organization that provides affordable and high quality generics while creating value for our customers, partners and stakeholders.”

In addition to this product, the Company currently markets 9 products licensed from various partners and has over 20 accepted ANDA filings, representing $2.8 billion in sales, for the 12 months ending November 30, 2015, according to IMS Health.

About Vensun Pharmaceuticals, Inc.

Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was established in July 2011 and is an emerging pharmaceutical company developing a unique portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories. The Company is co-developing the products with a number of strategic partners in the US and overseas to leverage economies of scale to efficiently develop products and ultimately supply quality generic products to the marketplace cost effectively. The Company currently has over 20 filed ANDAs and has 14 products in active development. In addition to this proprietary product development program, Vensun has also in-licensed 24 products to expand and diversify its pipeline.

For more information regarding Vensun Pharmaceuticals, Inc. please visit www.vensunrx.com.